Today we announced a milestone in our AbbVie partnership, following advancement of lead candidates targeting a historically undruggable transcription factor. https://bit.ly/3WzOKxG
Frontier Medicines
生物技术研究
South San Francisco，CA 18,169 位关注者
Frontier Medicines is a biopharmaceutical company that “drugs the undruggable” to transform patients’ lives.
关于我们
Frontier Medicines, located in South San Francisco, CA and Boston, MA, is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable. We are deploying our technologies in chemoproteomics, covalent drug discovery, and machine learning to develop a pipeline of groundbreaking medicines against the most important drivers of disease. Our lead program targets both the activated and inactive forms of KRAS G12C, a validated driver in a number of cancers that until recently has been undruggable. Our pipeline embodies our vision of bolding advancing science to defeat disease, starting with cancer.
- 网站
-
https://frontiermeds.com/
Frontier Medicines的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- South San Francisco，CA
- 类型
- 私人持股
- 创立
- 2018
地点
Frontier Medicines员工
动态
-
ICYMI: This week, our CEO, Chris Varma, joined an esteemed panel to discuss "Oncology at its Finest“ at the World Medical Innovation Forum (WMIF). As a leader in pioneering new approaches to cancer treatment, Chris shared Frontier's mission to redefine what’s possible in oncology through precision medicine and breakthrough innovations. We’re proud to be at the forefront of developing cutting-edge therapies that have the potential to transform lives. Thank you to the WMIF for hosting such an important conversation about the future of cancer care. Together, we’re shaping the next era of oncology. #PrecisionMedicine #chemoproteomics #BiotechBreakthroughs
-
-
At Frontier Medicines, we believe in making a difference in health and beyond. This week, we’re proud to highlight our Chief People Officer, Monique Silva Bobadilla, who has been working tirelessly with her M2E Foundation to provide young children in rural Rwanda with access to high-quality education. Monique’s passion for empowering communities goes hand in hand with our bold mission to drive innovation. Join us in celebrating Monique’s inspiring work as she continues to change lives! #M2EFoundation #MakingADifference
We’re thrilled to welcome our co-founder Monique Silva Bobadilla for an intensive coaching session this week as we prepare for the official launch of our new School Leaders Program in 8 schools next week in Musanze and Rutsiro District respectively. Monique has over 20 years of experience in strategic leadership, talent development, change management and innovation. She brings invaluable expertise in building high-performing teams and fostering innovation. This week’s training will be crucial in finalizing the curriculum and tailoring it for primary school leaders. Monique’s collaboration will ensure our selected team of M2E Education Specialists are fully prepared.
-
-
We are at the Cantor Fitzgerald Global Healthcare conference this week. We hope to see you there! #precisionmedicines, #chemoproteomics, #biotech
-
-
Congrats to our own Daniel Erlanson!
We are pleased to welcome Dr. Daniel Erlanson to the Drug Hunter Scientific Advisory Board! ? Dr. Erlanson brings over 25 years of experience in the biotech industry. Currently, he is Chief Innovation Officer of Frontier Medicines. Before that he co-founded and led chemistry at Carmot Therapeutics, Inc. Therapeutics, which collaborated with Amgen on the discovery of the first FDA-approved KRASG12C inhibitor, sotorasib. Carmot also put three of its own internally discovered drugs into the clinic before being acquired by Roche in early 2024.? ? Daniel is a widely recognized thought leader in fragment-based drug discovery (FBDD), serving as the editor of the popular Practical Fragments blog (https://lnkd.in/dStCAyZW), co-editor of two books on FBDD, and the inventor or author on over 70 granted US patents and peer-reviewed publications. ? Daniel started his industry career at Sunesis Pharmaceuticals, Inc., where he co-invented the covalent disulfide tethering approach for finding fragments and advancing them to leads, enabling the discovery of drugs for targets once thought to be intractable for small molecules, such as KRAS. Daniel received his BA in chemistry from Carleton College, his PhD from Harvard University in the laboratory of Greg Verdine, and did postdoctoral work in Jim Wells’ group at Genentech. ? We are privileged to have Daniel Erlanson on our Scientific Advisory Board, whose scientific leadership enhances Drug Hunter in our mission to empower the world’s scientists to make tomorrow’s medicines. ? Welcome Daniel!
-
-
Today we announced the appointment of Gerardo Ubaghs Carrión as Chief Financial Officer (CFO) and the close of a $20 million extension to our Series C, bringing the total amount raised to $100 million, with the financing slated to accelerate multiple pipeline programs. Learn more here: Learn more here: https://bit.ly/3KX9Pf2 #biotech #precisionmedicine #computationalchemistry
-
-
See you soon in Chicago! #ASCO24 #precisionmedicine #oncology
-